CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

and that can turn into enviable share price appreciation in the coming decades. Rachel Warren is a contributing Motley Fool stock market analyst covering pharmaceuticals, biotechnology, medical ...

The most recent analyst rating on (CRBU) stock is a Hold with a $2.50 price target. To see the full list ... Inc. is a clinical-stage biopharmaceutical company focused on CRISPR genome-editing ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

The stock of biotechnology firm Intellia Therapeutics has experienced a severe downturn after US regulators imposed a ...

Ark Invest Block Inc shares purchase totals $30.9M across ARKK, ARKW, and ARKF, as Cathie Wood boosts exposure to crypto and ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that ...

The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.

Kimberly-Clark Corp. will acquire Tylenol maker Kenvue Inc. in a cash and stock deal valued at almost $49 billion the two companies announced Nov. 3.

Explore DEFSEC Technologies stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DFSC. Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in ...

Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...